Last reviewed · How we verify
FF/UMEC/VI (200/62.5/25) mcg
FF/UMEC/VI (200/62.5/25) mcg is a Triple combination inhaler (ICS/LAMA/LABA) Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Chronic obstructive pulmonary disease (COPD) maintenance treatment.
FF/UMEC/VI is a triple combination inhaler that relaxes airway smooth muscle and reduces airway inflammation through multiple mechanisms to improve breathing in chronic obstructive pulmonary disease.
FF/UMEC/VI is a triple combination inhaler that relaxes airway smooth muscle and reduces airway inflammation through multiple mechanisms to improve breathing in chronic obstructive pulmonary disease. Used for Chronic obstructive pulmonary disease (COPD) maintenance treatment.
At a glance
| Generic name | FF/UMEC/VI (200/62.5/25) mcg |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Triple combination inhaler (ICS/LAMA/LABA) |
| Target | M3 muscarinic receptor, beta-2 adrenergic receptor, glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | Phase 3 |
Mechanism of action
Fluticasone furoate (FF) is an inhaled corticosteroid that reduces airway inflammation. Umeclidinium (UMEC) is a long-acting muscarinic antagonist that relaxes airway smooth muscle by blocking M3 receptors. Vilanterol (VI) is a long-acting beta-2 agonist that further relaxes airway smooth muscle. Together, these three agents provide complementary bronchodilation and anti-inflammatory effects.
Approved indications
- Chronic obstructive pulmonary disease (COPD) maintenance treatment
Common side effects
- Tremor
- Headache
- Palpitations
- Oral candidiasis
- Nasopharyngitis
Key clinical trials
- A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma (PHASE3)
- A Long-term Safety Study of Fixed Dose Combination Therapy Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate in Japanese Subjects With Asthma (PHASE3)
- Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Using the Connected Inhaler System (CIS) as Compared With Fluticasone Proprionate/ Salmeterol (FP/SAL) Plus Tiotropium (TIO) in Inadequately Controlled Asthma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FF/UMEC/VI (200/62.5/25) mcg CI brief — competitive landscape report
- FF/UMEC/VI (200/62.5/25) mcg updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about FF/UMEC/VI (200/62.5/25) mcg
What is FF/UMEC/VI (200/62.5/25) mcg?
How does FF/UMEC/VI (200/62.5/25) mcg work?
What is FF/UMEC/VI (200/62.5/25) mcg used for?
Who makes FF/UMEC/VI (200/62.5/25) mcg?
What drug class is FF/UMEC/VI (200/62.5/25) mcg in?
What development phase is FF/UMEC/VI (200/62.5/25) mcg in?
What are the side effects of FF/UMEC/VI (200/62.5/25) mcg?
What does FF/UMEC/VI (200/62.5/25) mcg target?
Related
- Drug class: All Triple combination inhaler (ICS/LAMA/LABA) drugs
- Target: All drugs targeting M3 muscarinic receptor, beta-2 adrenergic receptor, glucocorticoid receptor
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Respiratory/Pulmonology
- Indication: Drugs for Chronic obstructive pulmonary disease (COPD) maintenance treatment
- Compare: FF/UMEC/VI (200/62.5/25) mcg vs similar drugs
- Pricing: FF/UMEC/VI (200/62.5/25) mcg cost, discount & access